Phase 2 Data: Barzolvolimab Performs Well in CIU Patients Who Are Refractory to Antihistamines
Barzolvolimab met all primary and secondary endpoints with high statistical significance in a Phase 2 study in chronic inducible urticaria (CIU). Celldex’s barzolvolimab is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity, which is required for mast cell function and survival. The data […]